

## Company Announcement

### Pro Medicus Signs Deal with vRad – One of the World’s Largest Radiology Groups

- Visage® 7 to become a central component of vRad's technology platform
- vRad employs more than 400 radiologists, reading approximately 7 million studies annually
- First phase of the Visage 7 rollout is to two East Coast radiology groups in the vRad Alliance with potential for others to follow
- Transaction-based model has significant upside for PME

Wednesday 8 May 2013

Leading e-health company Pro Medicus [ASX: PME] today announced its wholly-owned subsidiary, Visage Imaging Inc. ("Visage"), has signed a five-year agreement with vRad (Virtual Radiologic), one the world's largest radiology groups.

vRad, whose more than 400 radiologists read 7 million radiology studies annually, will implement the Visage 7 Enterprise Imaging Platform as a central component of its technology platform focused on delivering a real-time, 'read anywhere, read anytime' environment. This will enable vRad to dynamically orchestrate when and by whom studies are read from anywhere within their owned partner radiology groups (hospitals and offsite), as well as their vast teleradiology network.

"We performed an extensive analysis of the market before making our decision," said Jordan Halter, vRad's Vice President of Business and Clinical Strategy. "Visage 7's speed and clinical depth immediately impressed us and we couldn't be more excited. Visage is a key component of our new technology platform and will enable us to rapidly stream even the largest radiology cases, to the most appropriate radiologist for interpretation, while also providing the most comprehensive clinical tools available."

The first phase of Visage implementations are planned for Diagnostic Imaging, Inc. (DII) and the New York Radiology Alliance (NYRA), both part of the vRad Alliance Network.

Mr. Halter added, "I've been fortunate to be in Medical Imaging and Medical Informatics for many of the formative years and there is no doubt that the Visage viewer and architecture provides tremendous advantages and flexibility for those looking to thrive in a consolidating market."

Dr. Sam Hupert, CEO of Pro Medicus Ltd said, "We are extremely pleased to be part of this key initiative. vRad is leveraging the unique strengths of Visage 7 enabling their technology platform to meet the

dynamic needs of integrated hospital-based and remote reading requirements. It is a platform for the future, one that has unparalleled scalability, clinical depth and speed, all of which are critical especially in the highly competitive North American radiology market.”

Commenting on the commercial aspects of the deal, Dr Hupert said, “This is a key milestone for us. The first phase of the rollout is material in its own right yet represents a relatively small percentage of vRad’s overall volume, so there is potential for significant upside in this contract. A deal of this magnitude, with such a large and prominent client, helps put us firmly on the map in the US market.”

**For further information:**

Dr Sam Hupert  
Chief Executive Officer  
Pro Medicus Limited  
Ph: 03 9429 8800

**Media:**

Richard Allen  
Oxygen Financial Public Relations  
Level 13, 90 Collins Street  
Melbourne, 3000, Victoria, Australia  
Ph: 03 9915 6341

**About Pro Medicus Limited:**

Pro Medicus Limited [ASX: PME] is Australia’s leading medical IT and e-health provider. Founded in 1983, the company provides a full range of integrated software products and services to individual, corporate and public health providers. More than 26,000 doctors are now connected to the company’s e-health service, promedicus.net. A key growth area for the company is the adoption of its digital technology by radiology providers as they move away from analogue systems.

**About vRad:**

Virtual Radiologic (vRad) is a technology-enabled national radiology practice working in partnership with local radiologists and hospitals to optimize radiology’s pivotal role in patient care. vRad’s more than 400 radiologists serve over 2,000 facilities, reading 7 million studies annually. Delivering access to extensive subspecialty coverage, vRad contributes to improved quality of patient care. And with its next-generation technology, vRad enhances productivity, helping to lower the overall cost of care while expediting time to accurate diagnosis and treatment.